ENDRA Life Sciences Inc.
NDRA
$6.46
$1.1922.58%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -24.62% | -36.01% | -48.69% | 33.25% | 10.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.46% | -31.96% | -46.72% | 5.76% | -10.65% |
| Operating Income | 22.46% | 31.96% | 46.72% | -5.76% | 10.65% |
| Income Before Tax | 32.50% | 25.25% | 38.93% | 9.20% | 8.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 32.50% | 25.25% | 38.93% | 9.20% | 8.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 32.50% | 25.25% | 38.93% | 9.20% | 8.36% |
| EBIT | 22.46% | 31.96% | 46.72% | -5.76% | 10.65% |
| EBITDA | 22.50% | 32.06% | 46.90% | -5.96% | 10.40% |
| EPS Basic | 71.52% | 95.22% | 94.68% | 91.25% | 85.46% |
| Normalized Basic EPS | 77.57% | 95.37% | 94.86% | 87.51% | 81.47% |
| EPS Diluted | 71.22% | 95.22% | 94.68% | 91.24% | 85.46% |
| Normalized Diluted EPS | 77.37% | 95.37% | 94.86% | 87.51% | 81.47% |
| Average Basic Shares Outstanding | 113.25% | 178.64% | 292.32% | 881.52% | 13,112.18% |
| Average Diluted Shares Outstanding | 169.11% | 178.64% | 292.32% | 881.52% | 13,112.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |